- A Case of Malignant Insulinoma Resistant to Octreotide and Combination Chemotherapy.
-
Duk Kyu Kim, Hyuk Chan Kwon, Ju Il Lee, Do Young Kang, Jae Seok Kim, Hyo Jin Kim, Jong Seong Kim
-
J Korean Endocr Soc. 1994;10(3):300-305. Published online November 6, 2019
-
-
-
 Abstract
 PDF
- Insulinoma is insulin-secreting tumor that almost all originate in the pancreas and cause symptoms related to hypoglycemia. The documentation of metastatic lesions by imaging studies, is only accurate mean of diagnosing malignant insulinoma before surgical exploration. We experienced a case of malignant insulinoma with liver, adrenal glands, regional lymph nodes and multiple bone metastasis. Abdominal ultrasonography, computed tomography and liver, bone scanning were used to evaluate the disease. Tissue diagnosis was obtained by percutaneous needle biopsy of liver metastasis. The patient was treated with Octreotide therapy and combination chemotherapy(Streptozocin and 5-FU), but she did not respond to these regimen. Now, we present this case with the brief review of literatures.
- Quantitative Changes of Apoprotein Levels in Non - Insulin Dependent Diabetics.
-
Do Young Kang, Duk Kyu Kim
-
J Korean Endocr Soc. 1994;10(2):105-114. Published online November 6, 2019
-
-
-
Abstract
PDF
- The aim of this study was to evaluate the quantitative changes of apoprotein levels in non-insulin dependent diabetics.As the subjects of this study, 37 patients were selected among non-insulin dependent diabetics admitted to Dong-A University Hospital between March 1990 and February 1994. They were divided into two groups. One group(n=20) had the diabetic dyslipidemia(Group DD) and the other group(n=17) had no diabetic dyslipidemia(Group D). For the control, normal healthy persons(n=17) were studied.Plasma lipid and apoprotein levels of all the subjects were measured. The results were as follows;1) Apoprotein AI & AII levels were significantly decreased in Group DD compared with both Group D and Control, but there was no significant difference between Group D and Control.2) Apoprotein B levels were significantly decreased in both Group DD and Group D compared with Control, but there was no significant difference between Group DD and Group D. 3) Apoprotein CII levels were significantly increased in both Group DD and Group D compared with Control, but there was no significant difference between Group DD and Group D. 4) Apoprotein CIII levels were significantly increased in Group D compared with both Group DD and Control, but there was no significant difference between Group DD and Control. 5) Apoprotein E levels were not significantly different among three groups.These results suggest that NIDDM itself causes the level of apoprotein B to decrease and the level of apoprotein CII to increase, regardless of the associated diabetic dyslipidemia.
|
KES
